← Leaderboards
Martin Edwin Gleave
University Of California, San Francisco
$1,721,828
Attributed
$3,176,865
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $603.3K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,176,865 · 2
By mechanism
U01$2,533,932 · 1
P50$642,933 · 1
Top collaborators
- Susan Halabi5 shared
- Phillip G Febbo2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Susan Halabi$7,630,539
- Daniel B Vigneron$43,424,992
- Felix Yi-Chung Feng$6,764,664
- Nevan J Krogan$73,195,859
- Pamela L Paris$2,074,035
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightCombined Modality TherapyMalignant NeoplasmsProstatectomyPathway InteractionsMolecularGeneticMalignant Neoplasm Of ProstateNeoadjuvant TherapyProgramsTumorTissuesAndrogensPhenotypeEnrollmentFutureHigh RiskCancer TherapyBiological MarkersBiological ProcessBiobankBehaviorData SetDeprivation
Grant awards (8)
Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)$237,841
P50 · FY2025 · CA · contact PI
Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)$190,626
P50 · FY2024 · CA · contact PI
Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)$214,466
P50 · FY2023 · CA · contact PI
Validation of prognostic and pathway signatures in lethal prostate cancer$454,043
U01 · FY2015 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$440,421
U01 · FY2014 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$511,043
U01 · FY2013 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$525,083
U01 · FY2012 · CA
Validation of prognostic and pathway signatures in lethal prostate cancer$603,342
U01 · FY2011 · CA